Personalized cancer treatment may be entering a genuinely new era. The convergence of two transformative biotechnologies — CRISPR genome editing and mRNA vaccine platforms — is now being tested in actual patients with some of the most treatment-resistant cancers, and the early signals are meaningful enough to reframe how oncologists think about immune priming.
This review, drawing on a structured literature search spanning 2013–2025 across PubMed, Web of Science, and Scopus, synthesizes preclinical and early clinical evidence for combined CRISPR-mRNA cancer immunotherapy. The central mechanism involves using CRISPR editing to first sensitize tumors — by disrupting checkpoint pathways or restoring antigen presentation machinery — before deploying individualized mRNA neoantigen vaccines to train T-cells against those exposed targets. Preclinical models demonstrate that this sequential approach substantially amplifies T-cell responses compared to either intervention alone. Early-phase clinical trials in melanoma, non-small-cell lung cancer, and pancreatic cancer have confirmed technical feasibility and documented durable immune activation, though efficacy data remain preliminary.
What makes this review analytically significant is the framing around "evolution-aware" oncology — the idea that therapies must be designed to track tumor mutational drift, not simply target a static snapshot of cancer. This is a meaningful conceptual advance over first-generation checkpoint inhibitors, which can lose efficacy as tumors evolve immune escape variants. The CRISPR layer theoretically addresses this by restoring or amplifying the very antigens tumors suppress. Critical limitations remain substantial, however: delivery of CRISPR components to solid tumors in vivo is still an unsolved engineering challenge, manufacturing timelines for individualized neoantigen vaccines are clinically demanding, and off-target editing safety requires long-term surveillance. This review is confirmatory of a promising direction rather than paradigm-shifting on its own — the field still awaits Phase II or III efficacy data — but the convergence it documents is worth tracking closely by anyone following precision oncology.